SG Americas Securities LLC Acquires New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

SG Americas Securities LLC acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) during the 3rd quarter, Holdings Channel reports. The fund acquired 22,514 shares of the biopharmaceutical company’s stock, valued at approximately $835,000.

Several other institutional investors and hedge funds have also modified their holdings of PTCT. Allspring Global Investments Holdings LLC purchased a new position in shares of PTC Therapeutics during the first quarter valued at approximately $46,000. Quest Partners LLC purchased a new position in PTC Therapeutics during the second quarter worth approximately $128,000. Quarry LP raised its stake in PTC Therapeutics by 100.0% during the second quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 2,500 shares during the period. Lazard Asset Management LLC raised its stake in PTC Therapeutics by 268.9% during the first quarter. Lazard Asset Management LLC now owns 6,504 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 4,741 shares during the period. Finally, Headlands Technologies LLC raised its stake in shares of PTC Therapeutics by 83.2% in the 2nd quarter. Headlands Technologies LLC now owns 6,611 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 3,002 shares during the period.

Insider Transactions at PTC Therapeutics

In other news, CFO Pierre Gravier sold 2,269 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $34.02, for a total value of $77,191.38. Following the transaction, the chief financial officer now directly owns 53,531 shares in the company, valued at approximately $1,821,124.62. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

PTCT has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $53.00 price target on shares of PTC Therapeutics in a report on Thursday, June 20th. Royal Bank of Canada raised their price target on shares of PTC Therapeutics from $32.00 to $34.00 and gave the company a “sector perform” rating in a report on Friday, October 4th. Bank of America raised their price target on shares of PTC Therapeutics from $25.00 to $32.00 and gave the company an “underperform” rating in a report on Friday, June 21st. Barclays raised their price target on shares of PTC Therapeutics from $25.00 to $31.00 and gave the company an “equal weight” rating in a report on Friday, August 9th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $44.00 price target on shares of PTC Therapeutics in a report on Tuesday, October 8th. Three analysts have rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $40.08.

PTC Therapeutics Stock Performance

PTC Therapeutics stock opened at $39.00 on Friday. The firm’s 50-day moving average is $34.59 and its 200-day moving average is $33.19. PTC Therapeutics, Inc. has a 1 year low of $17.53 and a 1 year high of $41.81. The company has a market cap of $2.99 billion, a P/E ratio of -5.08 and a beta of 0.65.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.16). The firm had revenue of $186.70 million for the quarter, compared to the consensus estimate of $192.12 million. As a group, sell-side analysts predict that PTC Therapeutics, Inc. will post -5.09 earnings per share for the current year.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.